ATE340165T1 - Kombi-moleküle, welche eine inhibierende wirkung auf die signalübertragung und dna-schädigende eigenschaften haben - Google Patents

Kombi-moleküle, welche eine inhibierende wirkung auf die signalübertragung und dna-schädigende eigenschaften haben

Info

Publication number
ATE340165T1
ATE340165T1 AT02703421T AT02703421T ATE340165T1 AT E340165 T1 ATE340165 T1 AT E340165T1 AT 02703421 T AT02703421 T AT 02703421T AT 02703421 T AT02703421 T AT 02703421T AT E340165 T1 ATE340165 T1 AT E340165T1
Authority
AT
Austria
Prior art keywords
molecules
relates
present
combi
signal transmission
Prior art date
Application number
AT02703421T
Other languages
English (en)
Inventor
Bertrand J Jean-Claude
Fabienne Dudouit
Stephanie Matheson
Original Assignee
Univ Mcgill
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Mcgill filed Critical Univ Mcgill
Application granted granted Critical
Publication of ATE340165T1 publication Critical patent/ATE340165T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94—Nitrogen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Cosmetics (AREA)
AT02703421T 2001-02-26 2002-02-26 Kombi-moleküle, welche eine inhibierende wirkung auf die signalübertragung und dna-schädigende eigenschaften haben ATE340165T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US27086801P 2001-02-26 2001-02-26

Publications (1)

Publication Number Publication Date
ATE340165T1 true ATE340165T1 (de) 2006-10-15

Family

ID=23033147

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02703421T ATE340165T1 (de) 2001-02-26 2002-02-26 Kombi-moleküle, welche eine inhibierende wirkung auf die signalübertragung und dna-schädigende eigenschaften haben

Country Status (6)

Country Link
US (1) US7572798B2 (de)
EP (1) EP1366027B1 (de)
AT (1) ATE340165T1 (de)
CA (1) CA2439143A1 (de)
DE (1) DE60214828T2 (de)
WO (1) WO2002068396A1 (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100735639B1 (ko) * 2004-12-29 2007-07-04 한미약품 주식회사 암세포 성장 억제 효과를 갖는 퀴나졸린 유도체 및 이의제조방법
CA2663147A1 (en) 2006-09-11 2008-03-20 Curis, Inc. Substituted 2-indolinone as ptk inhibitors containing a zinc binding moiety
KR101433629B1 (ko) 2006-09-11 2014-08-27 쿠리스 인코퍼레이션 아연 결합 부분을 함유한 티로신 키나아제 억제제
CN101535279B (zh) 2006-09-11 2015-05-20 柯瑞斯公司 含锌结合基的喹唑啉基egfr抑制剂
US7547781B2 (en) 2006-09-11 2009-06-16 Curis, Inc. Quinazoline based EGFR inhibitors containing a zinc binding moiety
TW200922564A (en) 2007-09-10 2009-06-01 Curis Inc CDK inhibitors containing a zinc binding moiety
AU2008299896B2 (en) 2007-09-10 2012-02-02 Curis, Inc. Tartrate salts or complexes of quinazoline based EGFR inhibitors containing a zinc binding moiety
US8119616B2 (en) 2007-09-10 2012-02-21 Curis, Inc. Formulation of quinazoline based EGFR inhibitors containing a zinc binding moiety
CN101619043B (zh) * 2008-06-30 2013-06-05 和记黄埔医药（上海）有限公司 喹唑啉衍生物及其医药用途
US8426430B2 (en) * 2008-06-30 2013-04-23 Hutchison Medipharma Enterprises Limited Quinazoline derivatives
CN102485735B (zh) * 2010-12-02 2014-09-24 东莞南方医大代谢医学研发有限公司 6-果糖氨-4-芳胺基喹唑啉衍生物及其用途

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU661533B2 (en) * 1992-01-20 1995-07-27 Astrazeneca Ab Quinazoline derivatives

Also Published As

Publication number Publication date
US7572798B2 (en) 2009-08-11
CA2439143A1 (en) 2002-09-06
EP1366027B1 (de) 2006-09-20
DE60214828T2 (de) 2007-09-06
DE60214828D1 (de) 2006-11-02
WO2002068396A1 (en) 2002-09-06
US20040086907A1 (en) 2004-05-06
EP1366027A1 (de) 2003-12-03

Similar Documents

Publication Publication Date Title
CY1107054T1 (el) Ενωσεις διτοσυλικου αλατος κιναζολινης
ATE297733T1 (de) Quinazolinderivate für die behandlung durch t- zellen vermittelter krankheiten
HUP0301246A2 (hu) Humán véralvadási faktor VII változatai
ATE376835T1 (de) Verwendung von fucanen in der behandlung von adhäsion, arthritis und psoriasis
ATE313532T1 (de) Diaryl- und arylheteroarylharnstoffderivate als modulatoren des 5-ht2a-serotoninrezeptors, die sich zur prophylaxe und behandlung von damit im zusammenhang stehenden erkrankungen eignen
DE60218458D1 (de) Isochinolinon derivate als parp inhibitoren
CY1105460T1 (el) Παραγωγα ακετυλενιου που εχουν mlgur 5 ανταγωνιστικη δραση
DE60219793D1 (de) Methode zur behandlung von zytokinvermittelten erkrankungen
ATE455092T1 (de) Substituierte tetracyclin-verbindungen zur behandlung von malaria
ATE340165T1 (de) Kombi-moleküle, welche eine inhibierende wirkung auf die signalübertragung und dna-schädigende eigenschaften haben
NO20055741L (no) Nye kjemiske forbindelser
ITBO20020620A1 (it) Condotto multi-canale bioriassorbibile di rigenerazione del nervo e processo per preparare il medesimo.
ATE384699T1 (de) 2,6-chinolinyl- und 2,6-naphthylderivate und deren verwendungen zur behandlung von vla-4 bezogenen krankheiten
DE60231107D1 (de) Tetrahydro-pyrazinoä1,2-aüindole für die behandlung von krankheiten des zentralnervensystems
WO2003082268A3 (en) Hemiasterlin derivatives and uses thereof in the treatment of cancer
WO2002081745A3 (en) Genes involved in osteogenesis, and methods of use
NO20060420L (no) 2-aminobenzoylderivater
DE60131968D1 (de) PYRANOÄ2,3-cÜIMIDAZOÄ1,2-aÜPYRIDIN-DERIVATE ZUR BEHANDLUNG VON GASTROINTESTINALEN ERKRANKUNGEN
MXPA03010728A (es) Moleculas de proteina-2 relacionadas con b7 y uso de las mismas.
MXPA04000272A (es) Derivados de 4-aminociclohexanol sustituidos.
WO2005016958A3 (en) Compounds for treating tumors
MXPA04001977A (es) Antagonistas v de receptor ccr-3.
ATE423780T1 (de) Makrozyclen zur behandlung von krebserkrankungen
ATE272400T1 (de) Verwendung von tryptophan-derivaten zur spezifischen zytostatischen behandlung von serotonin-produzierenden tumoren
CO5150221A1 (es) Nuevas 3-fenoxi- y 3-fenilalquiloxi-2-fenil-propilaminas sustituidas

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties